NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of...
Hence then, the article about inxmed announces promising phase ib ii clinical data for ifebemtinib kras g12c inhibitor in kras g12c mutant solid tumors at asco 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025 )
Also on site :
- My Daughter’s Friend Has a Crush on My Husband. It’s Making Us Both Deeply Uncomfortable.
- Maga’s biggest fear is coming true and Trump won’t survive it
- Governor Hochul: Annual statewide donation drive is complete